TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501 ...

17:29 EDT C4 Therapeutics (CCCC) files to sell 4.87M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Analysts expect adjusted earnings to reach $-2.767 per share for the current fiscal year. Nurix Therapeutics Inc does not currently pay a dividend. AAII’s proprietary stock grades come with A+ ...

Company reports second quarter 2024 financial resultsMALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company ...

Also Read: Monte Rosa Therapeutics’ AI And Machine Learning ... Price Action: GLUE stock is up 30.1% at $6.35 during the premarket session at last check Monday.

Even though Intellia Therapeutics stock traded lower by 20% on the back of news of its release of a phase 1/2 study using NTLA-2002 for the treatment of patients with HAE, I believe this creates a ...

Viking Therapeutics (NASDAQ: VKTX) was an outlier on the stock exchange Thursday, in the best way possible. Within its latest earnings release, the biotech had some encouraging news to report ...